Thymia

Thymia operates at the intersection of mental health software, digital diagnostics, and voice AI. Its earlier product description emphasizes clinician-facing depression assessment using video, speech, and game-inspired tasks; its current website positioning describes a broader voice-biomarker layer intended to detect signals across respiratory, neurological, cardiovascular, metabolic, and musculoskeletal systems. That breadth distinguishes its stated direction from a narrowly focused mental health assessment tool, while the policy reasoner and deployment options are presented as ways to interpret results in context and fit different voice environments. The company reports six years of research and development and clinical validation, and describes a team spanning neuroscience, AI, engineering, and speech. It has raised $5,563,614 across three rounds, with Kodori AG and Calm/Storm VC identified as lead investors. Its competitive position is therefore best characterized by its stated focus on short-sample, real-time voice analysis and infrastructure designed for integration into healthcare and other voice-enabled systems, rather than by a verified market-share claim.

Thymia’s financing history shows an early funding step in 2021, followed by two reported transactions in July 2023. The 2021 pre-seed round raised $1,078,607, with Calm/Storm VC and Kodori AG listed as leads. In July 2023, the company announced a $3,070,400 seed round and a separate $1,414,607 equity crowdfunding round, bringing structured total funding to $5,563,614 across three rounds. The seed round is the largest recorded transaction. The product narrative appears to have broadened: an earlier description centers on gamified, multimodal depression assessment for clinicians, while the website now presents voice biomarkers as applicable across several physical and mental health domains, supported by streaming analysis and a policy reasoner. A Sep 29, 2026 article about short recordings and type 2 diabetes screening is a possible signal of this broader application area, not confirmation of a launched product. Employee information is limited to a 11–50 band and a 2024 gender-diversity sourcing recognition; no reliable growth rate can be inferred.